Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Summary

Polyplus-transfection® launches versatile and powerful transfection reagent for DNA and siRNA

jetPRIME® expands rich catalogue of innovative reagents

Strasbourg, France, May 11th, 2009 – Polyplus-transfection® SA, a company specialized in research, development and marketing of innovative reagents for transfection and nucleic acid-based therapies, today announced the launch of jetPRIME®, a new versatile and powerful reagent for DNA and siRNA transfection.

jetPRIME® brings pharmaceutical and biotechnology researchers a number of advantages over most competitive offerings in the marketplace for day-to-day transfection experiments. The versatile reagent may be used for DNA as well as siRNA transfection in order to conduct transient gene expression studies and gene silencing by RNA interference. jetPRIME® is very efficient regardless of the nucleic acid delivered and gentle to cells because it uses smaller amounts of both nucleic acid and reagent compared to most reagents on the market. Furthermore, jetPRIME® is adapted to co-transfection of DNA and siRNA.

“Today’s announcement of jetPRIME® brings a significant new extension to our range and demonstrates Polyplus-transfection’s ability to develop powerful transfection reagents,” said Frédéric Perraud, CEO of Polyplus-transfection. “It also shows our commitment to continually improve our core business – the development of innovative solutions for transfection and therapeutic nucleic acid delivery.”

Note to editors

Gene transfection consists in introducing a plasmid into the nucleus of a cell to produce a protein that may affect the cell. Understanding gene function potentially leads to the development of therapeutic strategies against diseases. Transient gene transfection is also a means of producing viruses or recombinant proteins used in therapy.

In contrast, siRNA transfection only requires delivery of siRNA into the cytoplasm of a cell to block gene expression. The ability to silence a gene permits the understanding of its function, and helps learning about mechanisms of disease caused by the misregulation of specific genes.

Polyplus-transfection – jetPRIME launch (English version)

Polyplus-transfection – jetPRIME launch (French version)